Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard H Feldman

Showing results (1-10 of 160) with videos related to

Pageof 16
Sort By:
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 2, 2007
Primary prevention and delay of onset of AD/dementiaHoward H Feldman, Claudia Jacova
Nature Clinical Practice. Neurology|February 5, 2009
Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?Howard H Feldman, Claudia Jacova
Journal of the Neurological Sciences|March 27, 2009
Therapeutic potential of statins in Alzheimer's diseaseNagaendran Kandiah, Howard H Feldman
CNS Spectrums|June 21, 2008
Early identification of Alzheimer's disease: what have we learned from mild cognitive impairment?Howard H Feldman, Nagaendran Kandiah
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|July 16, 2005
Assessing mental status in dementia: the behavioral neurology assessment--right time? Right place?Howard H Feldman, Claudia Jacova
Journal of Neurology, Neurosurgery, and Psychiatry|March 14, 2007
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's diseaseHoward H Feldman, Roger Lane,
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 9, 2005
Mild cognitive impairmentHoward H Feldman, Claudia Jacova
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|April 21, 2017
The Canadian dementia challenge: Ensuring optimal care and services for those at risk or with dementia throughout the countryHoward H Feldman, Carole A Estabrooks
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 2, 2007
Is mild cognitive impairment a valid target of therapyKenneth Rockwood, Howard Chertkow, Howard H Feldman
Nature Reviews. Neurology|May 20, 2022
CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer diseaseDavid Knopman, Mary Sano, Howard H Feldman
Pageof 16

Showing results (1-10 of 160) with videos related to

Sort By:
Pageof 16
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 2, 2007
Primary prevention and delay of onset of AD/dementiaHoward H Feldman, Claudia Jacova
Nature Clinical Practice. Neurology|February 5, 2009
Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?Howard H Feldman, Claudia Jacova
Journal of the Neurological Sciences|March 27, 2009
Therapeutic potential of statins in Alzheimer's diseaseNagaendran Kandiah, Howard H Feldman
CNS Spectrums|June 21, 2008
Early identification of Alzheimer's disease: what have we learned from mild cognitive impairment?Howard H Feldman, Nagaendran Kandiah
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|July 16, 2005
Assessing mental status in dementia: the behavioral neurology assessment--right time? Right place?Howard H Feldman, Claudia Jacova
Journal of Neurology, Neurosurgery, and Psychiatry|March 14, 2007
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's diseaseHoward H Feldman, Roger Lane,
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 9, 2005
Mild cognitive impairmentHoward H Feldman, Claudia Jacova
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|April 21, 2017
The Canadian dementia challenge: Ensuring optimal care and services for those at risk or with dementia throughout the countryHoward H Feldman, Carole A Estabrooks
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 2, 2007
Is mild cognitive impairment a valid target of therapyKenneth Rockwood, Howard Chertkow, Howard H Feldman
Nature Reviews. Neurology|May 20, 2022
CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer diseaseDavid Knopman, Mary Sano, Howard H Feldman
Pageof 16